孟鲁司特钠联合布地奈德混悬液雾化吸入治疗咳嗽变异型哮喘75例的临床研究  

The clinial research on montelukast combed with budesonide aerosol inhalation in treatment of 75 cases of cougf variant asthma

作　　者：李立维[1] 朱艳玲 刘双敬[1] 李桂仙[1] 黄素坤[3] 

机构地区：[1]保定市第一中心医院重症医学科,河北保定071000 [2]河北省徐水县石油物探中心医院内一科,河北保定072555 [3]保定市第一中心医院诊科,河北保定071000

出　　处：《东南国防医药》2015年第1期61-63,共3页Military Medical Journal of Southeast China

摘　　要：目的探讨孟鲁司特钠联合布地奈德混悬液雾化吸入治疗咳嗽变异型哮喘(CVA)的临床疗效。方法 75例CVA患者随机分为对照组和研究组。对照组36例,给予常规基础治疗和布地奈德混悬液雾化吸入;研究组39例,在对照组基础上给予孟鲁司特钠口服。观察治疗前、治疗10 d后临床疗效及肺活量(FVC)、最大呼气峰流速(PEF)及超敏C反应蛋白(hs CRP)、肿瘤坏死因子-α(TNF-α)和白介素-13(IL-13)水平变化。结果治疗前两组患者FVC、PEF及hs CRP、TNF-α和IL-13水平比较,差异无统计学意义(P>0.05)。治疗10 d后,研究组FVC、PEF升高幅度明显优于对照组(P<0.05),血清hs CRP、TNF-α、IL-13水平明显低于对照组(P<0.05),研究组治疗总有效率94.87%明显高于对照组总有效率77.78%(P<0.05)。结论孟鲁司特钠联合布地奈德混悬液雾化吸入治疗咳嗽变异型哮喘疗效显著、不良反应较少,明显改善哮喘、咳嗽等临床症状。Objective To observe the clinical efficacy of montelukast combined with budesonide aerosol in the treatment of 75 cases cough variant asthma （CVA）.Methods 75 patients with CVA were randomly divided into the control group （36 cases）, which were given budesonide aerosol inhalation at the basis of conventional therapy , and the study group （39 cases）, which were given mon-telukast on the basis of the control group .The two groups were observed for the change of the clinical efficacy , FVC, PEF, hsCRP, TNF-α, IL-13 after treatment 10 days.Results There was no difference in FVC , PEF, hsCRP, TNF-α, IL-13 in the two groups be-fore treatment （P〉0.05）.The expression of FVC and PEF was increased significantly （P〈0.05）, and the expression of hsCRP, TNF-α, and IL-13 was decreased significantly in the study group than the control group after treatment 10 days （P〈0.05）.The clini-cal efficacy in the study group was better than that in the control group （94.87%vs.77.78%, P〈0.05）.Conclusion Montelukast sodium combined with budesonide inhalation could significantly improve cough variant asthma , greatly improve the clinical symptoms such as asthma, cough, and there were less adverse reaction .

关 键 词：孟鲁司特钠 布地奈德混悬液 咳嗽变异型哮喘 

分 类 号：R562.25[医药卫生—呼吸系统]